ArQule ( ARQL)

Drug:ARQ 197

Abstract No.LBA7502

Indication: Non-small cell lung cancer

Clinical Trial: Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-negative patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Presentation Time: Saturday, June 5. Oral session.

Notes: Arqule announced top-line results from this phase II study of ARQ 197 at the end of March.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today